Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism

@article{White2008RiskOF,
  title={Risk of fatal pulmonary embolism was 0.49 per 100 person-years after discontinuing anticoagulant therapy for venous thromboembolism},
  author={Richard H. R. White},
  journal={Evidence Based Medicine},
  year={2008},
  volume={13},
  pages={154 - 154}
}
ED FROM Douketis JD, Gu CS, Schulman S, et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007;147:766–74. Correspondence to: Dr J D Douketis, St Joseph’s Healthcare, Hamilton, Ontario, Canada; jdouket@mcmaster.ca Source of funding: no external funding. c Clinical impact ratings: Respirology 7/7; IM/Ambulatory care 6/7; Haematology 6/7 Recurrent venous thromboembolism (VTE) in patients who have discontinued… Expand

References

SHOWING 1-5 OF 5 REFERENCES
Death due to recurrent thromboembolism among younger healthier individuals hospitalized for idiopathic pulmonary embolism.
TLDR
In this cohort of younger patients with idiopathic PE, the rate of death due to recurrent VTE, particularly to first-time recurrent PE, was low and among the patients who died of thromboembolism >28 days after the index PE, 28% had developed pulmonary hypertension. Expand
Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism
TLDR
A multicenter randomized trial to evaluate the long-term clinical benefit of extending a 3-month course of oral anticoagulant therapy to 6 months or to 1 year in patients with a first episode of pulmonary embolism. Expand
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
TLDR
This chapter about treatment for venous thromboembolic disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) and indicates that the benefits do or do not outweigh risks, burden, and costs. Expand
[Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy)].
TLDR
The overall rate of bleeding events recorded in the present study was much lower than that recorded in other (including recent) observational and experimental studies, indicating that OAT has become safer in recent years, particularly if monitored in special anticoagulation clinics. Expand
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th Edition)
  • Chest
  • 2008